Research programme: cancer vaccines - MGI Pharma Biologics/sanofi pasteur
Latest Information Update: 08 Apr 2022
At a glance
- Originator MGI Pharma Biologics; sanofi pasteur
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Jan 2005 Aventis Pasteur is now called sanofi pasteur
- 31 Dec 2004 ZYCOS has been acquired by MGI Pharma and is now called MGI Pharma Biologics
- 27 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis